MXD1 and carcinoma: Thus, 1,25-(OH)2D3 represses MYC expression via direct [124] or indirect transcriptional inhibition by antagonism of the Wnt/β-catenin pathway [125,126], the induction of cystatin D [127] or the MYC antagonist MAD/MXD1 [128], by repressing long non-coding (lnc)RNA CCAT2 [129] or by promoting MYC protein degradation [130] in several carcinoma cell types.